Liberty Hudson Valley Dialysis is a medicare approved dialysis facility center in Newburgh, New York and it has 17 dialysis stations. It is located in Orange county at 4 Corwin Court, Newburgh, NY, 12550. You can reach out to the office of Liberty Hudson Valley Dialysis at (845) 562-7711. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Liberty Hudson Valley Dialysis has the following ownership type - Profit. It was first certified by medicare in October, 2010. The medicare id for this facility is 332674 and it accepts patients under medicare ESRD program.
| Name | Liberty Hudson Valley Dialysis |
|---|---|
| Location | 4 Corwin Court, Newburgh, New York |
| No. of Dialysis Stations | 17 |
| Medicare ID | 332674 |
| Managed By | Independent |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 4 Corwin Court, Newburgh, New York, 12550 | |
| (845) 562-7711 | |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
| NPI Number | 1346572153 |
| Organization Name | Liberty Hudson Valley Dialysis |
| Doing Business As | Lsl Newburgh Llc |
| Address | 4 Corwin Ct Newburgh, New York, 12550 |
| Phone Number | (845) 562-7711 |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 57% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 21% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 22% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 58% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 14% |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 58% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 17% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 25% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 57% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 23% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 20% | 12% |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 71% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 29% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 63% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 16% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 12% |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 102 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 17 |
| Medicare patients who had average hemoglobin (hgb) greater than 12 g/dL | 1 |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 143 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1348 |
| Percentage of adult patients getting regular hemodialysis at the center | 93 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
| Adult patients getting regular peritoneal dialysis at the center | 19 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 169 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 98 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Liberty Hudson Valley Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 167 |
| Hypercalcemia patient months | 1566 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 177 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 30 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 33 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 18 |
| Patients with Serumphosphor greater than 7 mg/dL | 10 |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 130 |
| Patient months included in arterial venous fistula and catheter summaries | 1172 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 59 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 16 |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 148 |
| Hospitalization Rate in facility | 193.7 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 284.4 |
| Hospitalization Rate: Lower Confidence Limit | 139.7 |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at Liberty Hudson Valley Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 22.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 28.8 |
| Readmission Rate: Lower Confidence Limit | 17.5 |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Liberty Hudson Valley Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.55 (As Expected) |
| SIR: Upper Confidence Limit | 2.34 |
| SIR: Lower Confidence Limit | .99 |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Liberty Hudson Valley Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 120 |
| Transfusion Rate in facility | 25.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 54.2 |
| Transfusion Rate: Lower Confidence Limit | 13.2 |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
The rate of mortality show you whether patients who were being treated regularly at Liberty Hudson Valley Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 775 |
| Mortality Rate in facility | 21.1 (Worse than Expected) |
| Mortality Rate: Upper Confidence Limit | 25.1 |
| Mortality Rate: Lower Confidence Limit | 17.6 |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago
Liberty Hudson Valley Dialysis Location: 4 Corwin Court, Newburgh, New York, 12550 Phone: (845) 562-7711 |
News Archive
A new molecular pathway involving the gene ZNF365 has been identified and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today.
In the search for a broadly acting pan-specific antiviral, an interdisciplinary team from Germany tested the previously proposed (for antiviral treatment against Influenza A infections) - Influenza A virus (IAV) defective interfering particles (DIPs). The research is published online on the bioRxiv preprint server.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today full year and fourth quarter results.
The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.
› Verified 3 days ago